Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 1.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 215,900 shares of the company’s stock after selling 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Bicycle Therapeutics were worth $3,023,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BCYC. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of Bicycle Therapeutics by 141.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 133,707 shares of the company’s stock valued at $3,026,000 after buying an additional 78,418 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at about $10,028,000. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at about $34,000. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at about $257,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Trading Down 3.5 %

BCYC stock opened at $11.25 on Tuesday. Bicycle Therapeutics plc has a 52 week low of $11.14 and a 52 week high of $28.67. The company has a market capitalization of $776.77 million, a price-to-earnings ratio of -3.42 and a beta of 0.93. The firm’s 50-day moving average is $13.51 and its two-hundred day moving average is $19.60.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at approximately $482,190. The trade was a 7.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Lee sold 9,038 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on BCYC shares. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. B. Riley decreased their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Finally, Stephens reissued an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.43.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.